# To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults

> **NCT04185090** · PHASE1 · UNKNOWN · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Hypertension
- Dyslipidemias

## Interventions

- **COMBINATION_PRODUCT:** ID1803
- **COMBINATION_PRODUCT:** ID1801
- **COMBINATION_PRODUCT:** ID1803+ID1801

## Key facts

- **NCT ID:** NCT04185090
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02
- **Primary completion:** 2020-04
- **Final completion:** 2020-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04185090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04185090, "To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04185090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*